Clopidogrel CPDG has been approved as a first line treatment for reducing major cardiovascular events such as death from cardiovascular origin, stent thrombosis, acute coronary syndrome, and recurrent revascularization 2.
El clopidogrel CPDG ha sido aprobado como indicación primaria para reducir eventos cardiovasculares mayores como muerte de origen cardiovascular, trombosis del stent, síndrome coronario agudo y revascularización recurrente 2.